Targeting gene therapy vectors to CNS malignancies

Journal of NeuroVirology

Volumn 4, Issue 2, 1998, Pages 133-147

  Spear, Matthew A ^a   Herrlinger, Ulrich ^a   Rainov, Nikolai ^a   Pechan, Peter ^a   Weissleder, Ralph ^a   Breakefield, Xandra O ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Brain tumor; CNS malignancies; Gene therapy; Glioblastoma; Glioma; Targeting; Vector

Indexed keywords

ANTIBODY; VIRUS VECTOR;

BRAIN TUMOR; CLONING VECTOR; CYTOTOXICITY; GENE TARGETING; GENE THERAPY; HUMAN; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW; TRANSCRIPTION REGULATION; TRANSGENE;

EID: 0031971635     PISSN: 13550284     EISSN: None     Source Type: Journal    
DOI: 10.3109/13550289809114514     Document Type: Review

References (179)

1. Aboody-Guterman K, Seena-Esteves M, Herrlinger U, Synder EY, Breakfield XO (1996). Visualization of brain tumor growth and neural cell migration in vivo using retroviral vectors expressing GFP. Soc Neurosci 22: 949.
2. Aho R, Jakanen S, Kalimo H (1994). CD44-hyaluronate interaction mediates in vitro lymphocyte binding to the white matter of the central nervous system. J Neuropath 53: 295-302.
3. Albritton LM, Tseng L, Scadden D, Cunningham JM (1995). A putative murine ecotropic retrovirus receptor gene encodes a multiple membrane-spanning protein and confers susceptibility to virus infection. Cell 57: 659-666.
4. Arbuthnot P, Bralet MP, Thamassin H, Danan JL, Brechot C, Ferry N (1995). Hepatoma cell-specific expression of a retrovirally transferred gene is achieved by alphfetoprotein but no insulinlike growth factor II regulatory sequences. Hepatology 22: 1788-1796.
5. Arteaga CL, Holt JT (1996). Tissue-targeted antisense c-fos retroviral vector inhibits established breast cancer xenografts in nude mice. Cancer Res 56: 1098-1103.
6. Bartus RT, Elliott PJ, Dean RL, Hayward NJ, Nagle TL, Huff MR, Snodgrass PA, Blunt DG (1996). Controlled modulation of BBB permeability using the bradykinin agonist, RMP-7. Exp Neurol 142: 14-28.
7. Ben-Shacher D, Yehuda S, Finberg JPM, Spanier I, Youdim MBH (1988). Selective alteration of the blood-brain barrier and insulin transport in iron-deficient rats. J Neurochem 50: 1434-1437.
8. Berens ME, Rutka JT, Rosenblum ML (1990). Brain tumor epidemiology, growth, and invasion. Neurosurg Clin N Am 1: 1-18.
9. 11C]methionine. J Comput Assist Tomogr 7: 1062-1066.
10. Besnard F, Brenner M, Nakatani Y, Chao R, Purohit HJ, Freese E (1991). Multiple interacting sites regulate astrocyte-specific transcription of the human gene for glial fibrillary acidic protein. J Biol Chem 266: 18877-18883.
11. 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Mel-14F(ab′)2 - a preliminary report. J Neurooncol 24: 109-122.
12. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampson-Johannes A, Fattaey A, McCormick F (1996). An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274: 373-376.
13. Boothman DA, Lee IW, Sahijdak WM (1994). Isolation of an x-ray-responsive element in the promoter region of tissue-type plasminogen activator: potential uses of x-ray-responsible elements for gene therapy. Rad Res 138: S68-71.
14. Boucher Y, Leunig M, Jain RK (1996). Tumor angiogenesis and interstitial hypertension. Cancer Res 56: 4264-4266.
15. Brach MA, Mass R, Sherman ML, Gunji H, Weichselbaum R, Kufe D (1991). Ionizing radiation induces expression and binding activity of the nuclear factor kappa b. J Clin Invest 88: 691-695.
16. Braselmann S, Graninger P, Busslinger M (1993). A selective transcriptional induction system for mammalian cells based on Ga14-estrogen receptor fusion proteins. Proc Natl Acad Sci 90: 1657-1661.
17. Brenner M, Kisseberth WC, Su Y, Besnard F, Messing A (1994). GFAP promoter directs astrocyte-specific expression in transgenic mice. J Neurosci 14: 1030-1037.
18. Camp BJ, Dyhrman ST, Memoli VA, Mott LA, Barth RJ (1996). In situ cytokine production by breast cancer tumor-infiltrating lymphocytes. Annals of Surgical Oncology 3: 176-184.
19. Chen L, Chen D, Manome Y, Dong Y, Fine HA, Kufe DW (1995). Breast cancer selective gene expression and therapy mediated by recombinant adenoviruses containing the DF3/MUC1 promoter. J Clin Invest 96: 2775-2782.
20. Cheng PW (1996). Receptor Ligand-facilitated gene transfer: enhancement of liposome-mediated gene transfer and expression by transferrin. Hum Gene Ther 7: 275-282.
21. Chiocca EA, Andersen J, Takamiya Y, Martuza R, Breakefield XO (1994). Virus-mediated genetic treatment of rodent gliomas. In Gene Therapeutics. Wolf JA (ed.). Birkhauser: Boston, pp. 245-262.
22. Chu TH, Marinez I, Sheay WC, Dornberg R (1994). Cell targeting with retroviral vector particles containing antibody-envelope fusion proteins. Gene Therapy 1: 292-299.
23. Cole DJ, Weil DP, Shilyanski J, Custer M, Kawakami Y, Rosenberg SA (1995). Characterization of the functional specificity of a cloned T-cell receptor heterodimer recognizing the MART-1 melanoma antigen. Cancer Res 55: 748-752.
24. Cosset FL, Morling FJ, Takeuchi Y, Weiss RA, Collins MK, Russell SJ (1995). Retroviral retargeting by envelopes expressing an N-terminal binding domain. J Virol 69: 6314-6322.
25. Christiano R, Roth J (1996). Epidermal growth factor mediated DNA delivery into lung cancer cells via the epidermal growth factor receptor. Cancer Gene Ther 3: 4-10.
26. Culver KW, Ram Z, Walbridge S, Ishii H, Oldfield EH, Blaese RM (1992). In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 256: 1550-1552.
27. Datta R, Rubin E, Suchatme V, Qureshi S, Halahan D, Weichselbaum RR, Kufe DW (1992). Ionizing radiation activates transcription of the EGR1 gene via CArG elements. Proc Natl Acad Sci USA 89: 10149-10153.
28. DiMaio JM, Clary BM, Via DF Coveney E, Pappas TN, Lyerly HK (1994). Directed enzyme pro-drug gene therapy for pancreatic cancer in vivo. Surgery 116: 205-213.
29. Ding D, Toth M, Zhou Y, Parks C, Hoffman BJ, Shenk T (1993). Glial cell specific expression of the serotonin 2 receptor gene: selective reactivation of a repressed promoter. Brain Res Mol Brain Res 20: 181-191.
30. Doran SE, Dan Ren X, Betz AL, Pagel MA, Neuwelt EA, Roessler BJ, Davidson BL (1995). Gene expression from recombinant viral vectors in the CNS following blood-brain-barrier disruption. Neurosurgery 36: 965-970.
31. Dore-Duffy P, Balabanov R, Washington R, Swanborg RH (1994). Transforming growth factor beta 1 inhibits cytokine-induced CNS endothelial cell activation. Mol & Chem Neuropath 22: 161-175.
32. Elliott PJ, Hayward NJ, Huff MR, Nagle TL, Black KL, Bartus RT (1996). Unlocking the blood-brain barrier: a role for RMP-7 in brain tumor therapy. Exp Neurol 141: 214-224.
33. Emanuel N, Kedar E, Bolotin EM, Smorodinsky NI, Barenholz Y (1996). Targeted delivery of duxorubicin via sterically stabilized immunoliposomes: pharmacokinetics and biodistribution in tumor-bearing mice. Pharm Res 13: 861-868.
34. Engelhardt B, Conley F, Kilshaw P, Butcher EC (1995). Lymphocytes infiltrating the CNS during inflammation display a distinctive phenotype and bind to VCAM-1 but not MAdCAM-1. Int Immunol 7: 481-491.
35. Ferrari G, Salvatori G, Rossi C, Cossu G, Mavilio F (1995). A retroviral vector containing a muscle-specific enhancer drives gene expression only in differentiated muscle fibers. Hum Gene Ther 6: 733-742.
36. Fisher B, Packard BS, Read EJ, Carrasquillo JA, Carter CS, Topalian SL, Yang JC, Yolles P, Larson SM, Rosenberg SA (1989). Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. J Clin Oncol 7: 250-261.
37. Fishman GI, Kaplan ML, Buttrick PM (1994). Tetracyclin-regulated cardiac gene expression in vivo. J Clin Invest 93: 1864-1868.
38. Fishman JB, Rubin JB, Handrahan JV, Connor JR, Fine RE (1987). Receptor-mediated transcytosis of transferrin across the blood-brain barrier. J Neurosci Res 19: 299-304.
39. Frieden PM (1993a). Receptor-mediated transport of peptides and proteins across the blood-brain barrier. The Blood-Brain Barrier. WM Pardridge (ed). Raven Press, Ltd.: New York, pp. 229-247.
40. Frieden PM, Walus LR, Musso GF, Taylor MA, Malfroy B, Starzyk RM (1991). Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier. Proc Natl Acad Sci USA 88: 4771-4775.
41. Frieden PM, Walus LR, Watson P, Doctrow SR, Kozarich JW, Backman C, Bergman H, Hoffer B, Bloom F, Granhom AC (1993b). Blood-brain barrier penetration and in vivo activity of an NGF conjugate. Science, 259: 373-377.
42. Gao L, Wagner E, Cotten M, Agarwal S, Harris C, Romer M, Miller L, Hu PC, Curiel D (1993). Direct in vivo gene transfer to airway epithelium employing adenovirus-polylysine-DNA complexes. Hum Gene Ther 4: 17-24.
43. Gazit G, Kane SE, Nichols P, Lee ES (1995). Use of the stress-inducible grp78/BiP promoter in targeting high level gene expression in fibrosarcoma in vivo. Cancer Res 55: 1660-1663.
44. Gherzi R, Carnemolla B, Siri A, Ponassi M, Balza E, Zardi L (1995). Human tenascin gene. Structure of the 5′-region, identification, and characterization of the transcription regulatory sequences. J Biol Chem 270: 3429-3434.
45. Gladson CL, Cheresh DA (1991). Glioblastoma expression of vitronectin and the alpha v beta 3 integrin. Adhesion mechanism for transformed glial cells. J Clin Invest 88: 1924-1932.
46. Gladson CL, Wilcox JN, Sanders L, Gillespie GY, Cheresh DA (1995). Cerebral microenvironment influences expression of the vitronectin gene in astrocytic tumors. J Cell Science 108: 947-956.
47. Goldsmith KT, Curiel DT, Engler JA, Garver RI (1994). Trans complementation of an E1A-deleted adenovirus with codelivered E1A sequences to make recombinant adenoviral producer cells. Hum Gene Ther 5: 1341-1348.
48. Goldstein DJ, Veller SK (1988). Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant. J Virol 62: 196-205.
49. Gossen M, Bujard H (1992). Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl. Acad Sci 89: 5547-5551.
50. Gossen M, Freundlieb S, Bender G, Muller G, Hillen W, Bujanrd H (1995). Transcriptional activation by tetracyclines in mammalian cells. Science 268: 1766-1769.
51. Gottschalk S, Cristiano R, Smith L, Wood SL (1994). Folate receptor-mediated DNA delivery and expression in vitro. Gene Ther 1: 185-191.
52. Gray KD, Roth MJ (1993). Mutational analysis of the envelope gene of Molonev murine leukemia virus. J Virol 67: 3489-3496.
53. Greenwood J, Wang Y, Calder VL (1995). Lymphocyte adhesion and transendothelial migration in the central nervous system: the role of LFA-1, ICAM-1, VLA-4 and VCAM-1. Immunol 86, 408-415.
54. Griffith KD, Read EJ, Carrasquillo JA, Carter CS, Yang JC, Fisher B, Aebersold P, Packard BS, Yu MY, Rosenberg SA (1989). In vivo distribution of adoptively transferred indium-111-labeled tumor infiltrating lymphocytes and peripheral blood lymphocytes in patients with metastatic melanoma. J Natl Cancer Inst 81: 1709-1717.
55. Gross G, Waks T, Eshar Z (1989). Expression of immunoglobulin T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA 86: 10024-10028.
56. Gutin PH, Prados MD, Phillips TL, Wara WM, Larson DA, Leibel SA, Sneed PK, Levin VA, Weaver KA, Silver P et al (1991). External irradiation followed by an intersittial high activity iodine-125 implant 'boost' in the initial treatment of malignant gliomas: NCOG study 6G-82-2. Int J Radiat Oncol Biol Phys 21: 601-606.
57. Hallahan DE, Kataoka Y, Kuchibhotla J, Virudachalam S, Weischelbaum R (1996). Tissue specific promoters improve the localization of radiation-inducible gene expression. Int J Radiat Oncol Biol Phys 36: (Suppl), 226 (abstr 136).
58. Hallahan DE, Mauceri HJ, Seung LP, Dunphy EJ, Wayne JD, Hanna NN, Toledano A, Helman S, Kufe DW, Weischelbaum RR (1995). Spatial and temporal control of gene therapy using ionizing radiation. Nat Med 8: 786-791.
59. Hallahan DE, Spriggs DR, Beckett MA, Kufe DW (1989). Increased tumor necrosis factor alpha mRNA after cellular exposure to ionizing radiation. Proc Natl Acad Sci USA 86: 10104-10107.
60. Han X, Kasahara N, Kan YW (1995). Ligand-directed retroviral targeting of human breast cancer cells. Proc Natl Acad Sci 92: 9747-9751.
61. Hatva E, Kaipainen A, Mentula P, Jaaskelainen J, Paetau A, Haltia M, Alitalo K (1995). Expression of endothelial cell-specific receptor tyrosine kinases growth factors in human brain tumors. Am J Path 146: 368-378.
62. Henson JW (1994). Regulation of the glial specific JC virus early promoter by the transcription factor Sp 1. J Biologic Chem 269: 1046-1050.
63. Higuchi M, Ohnishi T, Arita N, Hiraga S, Hayakawa T (1993). Expression of tenascin in human gliomas: its relation to histological malignancy, tumor dedifferentiation and angiogenesis. Acta Neuropathol 85: 481-484.
64. Huang K, Geoffroy JS, Singer MS, Rosen S (1991). A lymphocyte homing receptor (L-selectin) mediates the in vitro attachment of lymphocytes to myelinated tracts to the central nervous system. J Clin Invest 88: 1778-1783.
65. Hurford RK, Dranoff G, Mulligan RC, Tepper RI (1995). Gene Therapy of metastatic cancer by in vivo retroviral gene targeting. Nat Genetics 10: 430-435.
66. Huwyler J, Wu D, Pardridge WM (1996). Brain drug delivery of small molecules using immunoliposomes. Proc Natl Acad Sci 93: 14164-14169.
67. Hwu P, Rosenberg SA (1997). Gene therapy of cancer. In Cancer: principles and practice of oncology. Fifth edition. DeVita VT, Hellman S and Rosenberg SA (eds). Lippincott-Raven Publishers: Philadelphia, pp. 3005-3022.
68. Hwu P, Yang JC, Cowher R, Treisman J, Shafer GE, Eshar Z, Rosenberg SA (1995). In vivo antitumor activity of T-cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res 55: 3369-3373.
69. Hwu P, Yannelli J, Kriegler M, Anderson WF, Perez C, Chiang Y, Schwarz S, Cowherd R, Delgado C, Mule J et al (1993). Functional and molecular characterization of TIL transduced with TNFa cDNA for the gene therapy of cancer in man. J Immunol 150: 4104-4115.
70. Inamura T, Black KL (1994). Bradykinin selectively opens blood-tumor barrier in experimental brain tumors. J Cereb Blood Flow Metab 14: 862-870.
71. Inoue M, Plautz G, Shu S (1996). Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells. Cancer Res 56: 4702-4708.
72. Ioannides CG, Fisk B, Tomasovic B, Pandita R, Aggarwal BB, Freedman RS (1992). Induction of interleukin-2 receptor by tumor necrosis factor alpha on cultured ovarian tumor-associated lymphocytes. Cancer Immunol Immunother 35: 83-91.
73. Ishihara H, Tsuneoka K, Dimchev AB, Shikita M (1993). Induction of the expression of the interleukin-1 beta gene in mouse spleen by ionizing radiation. Radiat Res 133: 321-326.
74. Ito T, Recht L, Salimi A, Brill AB, Raso V, Griffin T (1991). Delivery of antitransferrin receptor MABS into human glioma xenografts: autoradiographic studies (abstr.). Proc Annu Meet Am Assoc Cancer Res 32: A1608.
75. Ikoh K, Tilden AB, Balch CM (1986). Interleukin 2 activation of cytotoxic T-lymphocytes infiltrating into human metastatic melanomas. Cancer Res 46: 3011-3017.
76. Jaworski DM, Kelly GM, Piepmeier JM, Hockfield S (1996). BEHAB (Brain Enriched Hyaluronan Binding) is expressed in surgical samples of glioma and in intracranial grafts of invasive glioma cell lines. Cancer Res 56: 2293-2298.
77. Jefferies WA, Brandon MR, Hunt SV, Williams AF, Gatter KC, Mason DY (1984). Transferrin receptor on endothelium of brain capillaries. Nature, 312: 162-163.
78. Kasahara NK, Dozy AM, Kan YW (1994). Tissue specific targeting of retroviral vectors through ligand-receptor interactions. Science 266: 1373-1375.
79. Kesari S, Randazzo BP, Valyi-Nagy T et al (1995). Therapy of experimental human brain tumors using a neuroattenuated herpes simplex virus mutant. Lab Invest 73: 636-648.
80. Kim JH, Kim SH, Kolzsvary BS, Brown SL, Kim OB, Freytag SO (1995). Selective enhancement of radiation response of herpes simplex virus thymidine kinase transduced 9L gliosarcoma cell in vitro and in vivo by antiviral agents. Int J Radiat Oncol Biol Phys 33: 861-868.
81. Kim JH, Kim SH, Brown SL, Freytag SO (1994). Selective enhancement by an antiviral agent of the radiation-induced cell killing of human glioma cells transduced with HSVtk gene. Cancer Res 54: 6053-6056.
82. Ko SC, Cheon J, Kao C, Gotoh A, Shirakawa T, Sikes RA, Karsenty G, Chung LWK (1996). Osteocalcin promoter-based toxic gene therapy for the treatment of osteosarcoma in experimental models. Cancer Res 56: 4614-4619.
83. Kondratyev AD, Chung KN, Jung MO (1996). Identification and characterization of a radiation-inducible glycosylated human early-response gene. Cancer Res 56: 1498-1502.
84. Kramer R, Zhang Y, Gehrmann J, Gold R, Thoenen H, Wekerle H (1995). Gene transfer through the blood nerve barrier: NGF-engineered neuritogenic T lymphocytes attenuate experimental autimmune neuritis. Nat Med 1: 1162-1166.
85. Kramm CM, Rainov NG, Sena-Esteves M, Barnett FH, Chase M, Herllinger U, Pechan P, Chiocca EA, Breakefield XO (1996). Long-term survival in a rodent model of disseminated brain tumors by combined intrathecal delivery of herpes vectors and ganciclovir treatment. Hum Gene Ther 7: 1989-1994.
86. Kramm CM, Sena-Esteves M, Barnett FH, Rainov NG, Schuback DE, Yu JS, Pechan PA, Paulus W, Chiocca EA, Breakefield XO (1995). Gene therapy for brain tumors. Brain Pathol 5: 345-381.
87. Krebs CJ, McAvoy MT, Kumar G (1994). The JC virus minimal core promoter is glial cell specific in vivo. J Virol 69: 2434-2442.
88. Kristiansen K, Hagen S, Kollevold T, Torvik A, Holme I, Nesbakken R, Hatlevoll R, Lindgren M, Brun A, Lindgren S, Notter G, Andersen AP, Eigen K (1981). Combined modality therapy of operated astrocytomas grade III and IV: confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 47: 649-652.
89. Kumagai T, Tanio Y, Osaki T, Horai T, Kishimoto T (1995). Gene therapy for small cell lung cancer cells over-expressing myc family oncogenes by tumour-specific expression of the herpes simplex virus thymidine kinase gene. Gene Ther 2: 33-41.
90. Kuppner MC, Hamou MF, de Tribolet N (1988). Immunohistological and functional analyses of lymphoid infiltrates in human glioblastomas. Cancer Res 48: 6926-6932.
91. Kurnick JT, Kradin RL, Blumberg R, Schneeberger EE, Boyle LA (1986). Functional characterization of T lymphocytes propagated from human lung carcinomas. Clin Immunol Immunopathol 38: 367-380.
92. Ladner RC, Guterman SK (1990). PCT patent application W090/02809.
93. Lafreniere R, Rosenberg SA (1985). Successful immunotherapy of mutine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin-2. Cancer Res 45: 3735-3741.
94. Lal B, Indurti RR, Couraud PO, Goldstein GW and Laterra J (1994). Endothelial cell implantation and survival within experimental gliomas. Proc Natl Acad Sci 91: 9695-9699.
95. Laske DW, Ilercil O, Akbasak A, Youle RJ, Oldfield EH (1994). Efficacy of direct intratumoral therapy with targeted protein toxins for solid human gliomas in nude mice. J Neurosurg 80: 520-526.
96. Lee CH, Liu M, Sie KL, Lee MS (1996). Prostate-specific antigen promoter driven gene therapy targeting DNA polymerase-a and topoisomerase lia in prostate cancer. Anticancer Res 16: 1805-1812.
97. 131I-labeled anti-tenascin monoclonal antibody 81C6. Cancer Res 48: 2904-2910.
98. Levine AJ, Momand J, Finlay CA (1991). The p53 tumour suppressor-gene. Nature 351: 453-456.
99. Levy AP, Lev NS, Wegner S, Goldberg MA (1955). Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J Biol Chem 270: 13333-13340.
100. Linington C, Berger T, Perry L, Weerth S, Hinze-Selch D, Zhang Y, Lu H, Lassmann H, Wkerle H (1993). T cells specific for the myelin oligodendricyte glycoprotein mediate an unusual auto immune inflammatory response in the central nervous system. Eur J Immunol 23: 1364-1372.
101. Lu B, Federoff HJ (1995). Herpes simplex virus type I amplicon vectors with glucocorticoid-inducible gene expression. Hum Gene Ther 6: 419-428.
102. Lubbe AS, Bergemann C, Riess H, Schriever F, Reichardt P, Possinger K, Matthias M, Dorken B, Herrmann F, Gurtler R, Hohenberger P, Haas N, Sohr R, Sander B, Lemke AJ, Ohlendorf D, Huhnt W, Huhn D (1996). Clinical experiences with magnetic drug targeting: a phase I study with 4′-epidoxorubicin in 14 patients with advanced solid tumors. Cancer Res 56: 4686-4693.
103. Martin M, Noel D, Valsesia-Wittman S, Brockly F, Etienne-Julan M, Russell S, Cosset FL, Piechaczyk M (1996). Targeted infection of human cells via major histocompatibility complex class I molecules by Moloney murine leukemia virus-derived viruses displaying single-chain antibody fragment-envelope fusion proteins. J Virol 70: 2957-2962.
104. Martell LA, Agrawal A, Ross DA, Muraszko KM (1993). Efficacy of transferrin receptor-targeted immunotoxins in brain tumor cell lines and pediatric brain tumors. Cancer Res 53: 1348-1353.
105. Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM (1991). Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252: 854-856.
106. Matsuoka S, Yamaguchi M, Hiyashi Y, Matsukage A (1993). Nucleotide sequence and promoter-specific effect of a negative regulatory region located upstream of the mouse proliferating cell nuclear antigen gene. Eur J Biochem 218: 173-181.
107. McKie EA, MacLean AR, Lewis AD et al (1996). Selective in vitro replication of herpes simplex virus type 1 (HSV-1) ICP34.5 null mutants in primary human CNS tumors- evaluation of potentially effective clinical therapy. Br J Cancer 75: 745-752.
108. Michael SI, Hong JS, Curiel DT, Engler JA (1995). Addition of a short peptide ligand to the adenovirus fiber protein. Gene Ther 2: 660-668.
109. Miescher S, Whiteside TL, Moretta L, von Fliedner V (1987). Clonal and frequency analyses of tumor-infiltrating T lymphocytes from human solid tumors. J Immunol 142: 4004-4011.
110. Miyao Y, Shimizu K, Moriuchi S, Yamada M, Nakahira K, Nakajima K, Nakao J, Kuriyama S, Tusjii T, Mikoshiba K, Hayakawa T, Ikenaka K (1993). Selective expression of foreign genes in glioma cells: use of the mouse myelin basic protein gene promoter to direct toxic gene expression. J Neurosci Res 36: 472-479.
111. Mule JJ, Shu S, Rosenberg SA (1984). Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science 225: 1487.
112. Myers RL, Ray SK, Eldridge R, Chotani MA, Chiu IM (1995). Functional characterization of the brain-specific FGF-1 promoter, FGF-1.B. J Biol Chem 270: 8257-8266.
113. Negrier S, Philip T, Stoter G, Fossa SD, Janssen S, Iacone A, Cleton FS, Eremin O, Israel L, Jasmin C et al (1989). Interleukin-2 with or without LAK cell in metastatic renal cell carcinoma: A report of a European multicentre study. Eur J Cancer Clin Onco 25: S21-28.
114. Nerrouche Y, Negrier S, Bain C, Combaret V, Mercatello A, Coronel B (1995). Clinical application of retroviral gene transfer in oncology: results of a French study with tumor-infiltrating lymphocytes transduced with the gene of resistance to neomycin. J Clin Oncol 13: 410-417.
115. Netti PA, Baxter LT, Boucher Y, Skalak R, Jain RK (1995). Time-dependent behavior of intersittial fluid pressure in solid tumors: implications for drug delivery. Cancer Res 55: 5451-5458.
116. Neuwelt EA, Hill SA (1987). Chemotherapy administered in conjunction with osmotic blood-brain barrier modification in patients with brain metastates. J Neuro-oncol 4: 195-207.
117. Nilaver G, Muldoon LL, Kroll RA, Pagel MA, Breakefield XO, Davidson BL, Neuwelt EA (1995). Delivery of herpesvirus and adenovirus to nude rat intracerebral tumors following osmotic blood-brain barrier disruption. Proc Natl Acad Sci 92: 9829-9833.
118. O'Neil KT, Hoess RH (1995). Phage display: protein engineering by directed evolution (review). Cur Opinion Struct Biol 5: 443-449.
119. Oldfield EH, Ram Z, Culver KW, Blaese RM, DeVroom HL, Anderson WF (1993). Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir. Hum Gene Ther 4: 39-69.
120. Osaki T, Tanio Y, Tachibana I, Hosoe S, Kumagai T, Kawase I, Oikawa S, Kisismoto T (1994). Gene therapy for carcinoembryonic antigen-producing human lung cancer cells by cell-type specific expression of herpes simplex virus thymidine kinase gene. Cancer Res 54: 5258-5261.
121. Ozaki K, Yoshida T, Ide H, Saito I, Ideda Y, Sugimura T, Terada M (1996). Use of von Willebrand factor promoter to transduce suicidal gene to human endothelial cells, HUVEC. Hum Gene Ther 7: 1483-1490.
122. Paine JT, Handa H, Yamasaki T, Yamashita J, Miyatake S (1986). Immunohistochemical analysis of infiltrating lymphocytes in central nervous system tumors. Neurosurg 18: 766-772.
123. Pang S, Dannul LJ, Kaboo R, Xie Y, Tso C, Michel K, deKernion JB, Belldegrun AS (1996). Identification of a positive regulatory element responsible for tissue-specific expression of prostate-specific antigen. Cancer Res 57: 495-499.
124. Papa MZ, Mule JJ, Rosenberg SA (1986). Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: Successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three distict histological types. Cancer Res 46: 4973-4978.
125. Parmley SF, Smith GP (1989). Antibody-selectable filamentous fd phage vectors: Affinity purification of target genes. Gene 73: 305-318.
126. Pasqualini R, Ruoslahti E (1996). Organ targeting in vivo using phage display peptide libraries. Nature 380: 364-366.
127. Paulus W, Baur I, Boyce FM, Breakefield XO, Reeves SA (1996). Self-contained, tetracycline-regulated retroviral vector system for gene delivery to mammalian cells. J Virol 70: 62-67.
128. Pechan PA, Fotaki M, Thompson RL, Dunn R, Chase M, Chiocca EA, Breakefield XO (1996). A novel 'piggyback' packaging system for herpes simplex virus amplicon vectors. Hum Gene Ther 7: 2003-2013.
129. Peter RU, Beetz A, Ried C, Michel G, van Beuningen D, Ruzicka T (1993). Increased expression of the epidermal growth factor receptor in human epidermal keratinocytes after exposure to ionizing radiation. Radiat Res 136: 65-70.
130. Plate KH, Breier G, Weich HA, Mennel HD, Risau W (1994). Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. Int J Cancer 59: 520-529.
131. Rabinowich H, Cohen R, Bruderman I (1987). Functional analysis of mononuclear cells infiltrating into tumors: lysis of autologous human tumor cells by cultured infiltrating lymphocytes. Cancer Res 47: 173-177.
132. Rainov NG, Zimmer C, Chase M, Kramm CM, Chiocca EA, Weissleder R, Breakefield XO (1995). Selective uptake of viral and monocrystalline particles delivered intra-arterially to experimental brain neoplasms. Hum Gene Ther 6: 1543-1552.
133. Rosenberg SA, Aebersold P, Cornetta K, Kasid A, Morgan RA, Moen R, Karson EM, Lotze MT, Yang JC, Topalian SL et al (1990). Gene transfer into humans-immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 323: 570-578.
134. Ruff M, Schiffman E, Terranova V, Pert CB (1985). Neuropeptides are chemoattractants for human tumor cells and monocytes: a possible mechanism for metastasis. Clin Immuno and Immunopath 37: 387-396.
135. Russel SJ, Hawkins RE, Winter G (1995). Retroviral vectors displaying functional antibody fragments. Nucleic Acids Res 21: 1081-1085.
136. Saris SC, Spiess P, Lieberman DM, Lin S, Walbridge S, Oldfield EH (1992). Treatment of murine primary brain tumors with systemic interleukin-2 and tumor-infiltrating lymphocytes. J Neurosurg 76: 513-519.
137. Schiffer D, Cavalla P, Dutto A, Borsotti L (1997). Cell proliferation and invasion in malignant gliomas. Anticancer Res 17: 61-69.
138. Schnierle BS, Groner G (1996a). Retroviral targeted delivery. Gene Ther 3: 1069-1073.
139. Schnierle BS, Moritz D, Jeschke M, Groner B (1996b). Expression of chimeric envelope proteins in helper cell lines and integration into Moloney murine leukemia virus particles. Gene Therapy 3: 334-342.
140. Schoof DD, Gramolini CA, Davidson DL, Massaro AF, Wilson RE, Eberlein TJ (1988). Adoptive immunotherapy of human cancer using low-dose recombinant interleukin-2 and lymphokine-activated killer cells. Cancer Res 48: 5007-5010.
141. Schwarzenberger P, Spence SE, Gooya JM Michiel D, Curiel DT, Ruscetti FW, Keller JR (1996). Targeted gene transfer to human hematopoietic progenitor cell lines through the c-kit receptor. Blood 87: 472-8.
142. Scott JK, Smith GP (1990). Searching for peptide ligands with an epitope library. Science 249: 386-390.
143. Sherman ML, Datta R, Hallahan DE, Weichselbaum RR, Kufe DW (1990). Ionizing radiation regulates expression of the c-jun protooncogene. Proc Natl Acad Sci USA 87: 5663-5666.
144. Shimizu K (1994). Selective gene therapy of malignant gliomas using brain-specific promoters: its efficacy and basic investigation. Nippon Rinsho (Japanese J Clin Med), 52: 3053-3058.
145. Shin TH, Paterson AJ, Kudlow JE (1995). p53 stimulates transcription from the human transforming growth factor alpha promoter: a potential growth-stimulatory role for p53. Mol Cell Bio 15: 4694-4701.
146. Short MP, Choi B, Lee J, Malick A, Breakefield XO, Martuza RL (1990). Gene delivery to glioma cells in rat brain by grafting of a retrovirus packaging cell line. J Neurosci Res 27: 427-439.
147. Shu S, Chou T, Rosenberg SA (1987). Generation from tumor-bearing mice of lymphocytes with in vivo therapeutic efficacy. J Immunol 139: 295-304.
148. Smith MJ, Rousculp MD, Goldsmith KT, Curiel DT, Garver RK (1994). Surfactant protein A-directed toxin gene kills lung cancer cells in vitro. Hum Gene Ther 5: 29-35.
149. Snyder EY, Deitcher DL, Walsh C, Arnold-Aldea S, Hartweig EA, Cepko CL (1992). Multipotent neuronal cell lines can engraft and participate in development of mouse cerebellum. Cell 68: 33-51.
150. Somia NV, Zoppe M, Verma IM (1995). Generation of targeted retroviral vectors by using single-chain variable fragment: an approach to in vivo gene delivery. Proc Natl Acad Sci 92: 7570-7574.
151. Spear MA, Li C, Weissleder R, Putney S, Pechan P, Breakefield XO (1997). Ox26 Monoclonal Antibody Targets HSV-1 Vector to Transferrin Receptor-Bearing Cells. Proc Am Assoc Cancer Res 38: 343(A2302).
152. Spear MA, Sakamoto KM, Herrlinger U, Pechan PP, Breakfield XO (1997). Function of the EGR-1 promoter in a minimal HSV-1 amplicon vector system Proc Am Soc Ther Rad Oncol (In press).
153. Stevens CW, Zeng M, Cerniglia GJ (1996). Ionizing radiation greatly improves gene transfer efficiency in mammalian cells. Hum Gene Ther 7: 1727-1734.
154. Takahashi JA, Fukumoto M, Igarashi K, Oda Y, Kikuchi H, Hatanaka M (1992). Correlation of basic fibroblast growth factor expression levels with the degree of malignancy and vascularity in human gliomas. J Neurosurg 76: 792-798.
155. Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC, Abraham JA (1991). The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 266: 11947-11954.
156. Urien S, Pinquier JL, Paquette B, Chaumet-Riffaud P, Kiechel JP, Tillement JP (1987). Effect of the binding of isradipine and darodapine to different plasma proteins and their transfer through the rat blood-brain barrier: drug binding to lipoproteins does not limit the transfer of drug. J Pharmacol Exp Ther 242: 349-353.
157. Ventimiglia JB, Wikstrand CJ, Ostrowdki LE, Bourdon MA, Lightner VA, Bigner DD (1992). Tenascin expression in human glioma cell lines and normal tissues. J Neuroimmunol 36: 41-55.
158. Vile RG, Miller N, Chernajovsky Y, Hart I (1994). Ca comparison of the properties of different retroviral vectors containing the mutine tyrosinase promoter to achieve transcriptionally targeted expression of the HSVtk or IL-2 genes. Gene Ther 1: 307-316.
159. Vile RG, Diaz RM, Miller N, Mitchell S, Russell SJ (1995). Tissue-specific gene expression form Mo-MLV retroviral vectors with hybrid LTRs containing the murine tyrosinase enhancer/promoter. Virology 214: 307-313.
160. Vile RG, Hart IR (1993). In vitro and in vivo targeting of gene expression to melanoma cells. Cancer Res 53: 962-967.
161. Vitolo D, Zerbe T, Kanbour A, Dahl C, Herberman RB, Whiteside TL (1992). Expression of mRNA for cytokines in tumor-infiltrating mononuclear cells in ovarian adenocarcinoma and invasive breast cancer. Int J Cancer 51: 573-580.
162. Wagner E, Zatloukal K, Cotten M, Kirlappos H, Mechtler K, Curiel DT, Birnstiel ML (1992). Coupling of adenovirus to transferrin-polylysine/DNA complexes greatly enhances receptor-mediated gene delivery and expression of transfected genes. Proc Natl Acad Sci 89: 6099-6103.
163. Walker MD, Alexander E, Hunt WE, MacCarty CS, Mahaley MS, Mealey J, Norrell HA, Owens G, Ransohoff J, Wilson CB, Gehan EA, Strike TA (1978). Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. J Neurosurg 49: 333-343.
164. Wang Q, Redovan C, Tubbs R, Olencki T, Klein E, Kudoh S, Finke J, Bukowski RM (1995). Selective cytokine gene expression in renal cell carcinoma tumor cells and tumor-infiltrating lymphocytes. Int J Cancer 61: 780-785.
165. Wang Y, Tsai SY, O'Malley BW (1994). A regulatory system for use in gene transfer. Proc Natl Acad Sci 91: 8180-8184.
166. Weijtens M, Willemsen R, Valerio D, Stam K, Bolhuis R (1995). Functional expression of a single chain Fv/g receptor with renal cell carcinoma specificity in activated human PBL; single chain antibody Fv fragment and FceRI receptor fusion gene expression in cytotoxic T-lymphocyte or peripheral blood lymphocyte using LXSN retro virus vector (abstract). J Mol Med 73: B13.
167. Weindel K, Moringlane JR, Marme D, Weich HA (1994). Detection and quantification of vascular endothelial growth factor/vascular permeability factor in brain tumor tissue and cyst fluid: the key to angiogenesis?
168. Weischelbaum RR, Hallahan DE, Becket MA, Hauceri HJ, Lee H, Sukhatme VP, Kufe DW (1994). Gene therapy targeted by radiation preferentially radiosensitizes tumor cells. Cancer Res 54: 4266-4269.
169. Weller M, Fontana A (1995). The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-B, T-cell apoptosis, and the immune privilege of the brain. Brain Res Rev 21: 128-151.
170. Weller RO, Engelhardt B, Phillips M (1996). Lymphocyte targeting of the central nervous system: a review of afferent and efferent CNS-immune pathways. Brain Pathology 6: 275-288.
171. Whelan J, Miller N (1996). Generation of estrogen receptor mutants with altered ligand specificity for use in establishing regulatable gene expression system. J Steroid Biochem Mol Biol 58: 3-12.
172. Wickham TJ, Segal DM, Roelvink PW, Carrion ME, Lizonova A, Lee GM, Kovesdi I (1996). Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies. J Virol 70: 6831-6838.
173. Yamada S, Ruscetti FW, Overton WR, Herberman RB, Birchenall-Sparks MC, Ortaldo JR (1987). Regulation of human large granular lymphocytes and T cell growth and function by recombinant interleukin 2. I. Induction of interleukin 2 receptor and promotion of growth of cells with enhanced cytotoxicity. J Leukocyte Biol 41: 505.
174. Yanase T, Tamura M, Fujita K, Kodama S, Tanaka K (1993). Inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and metastasis of human cell lines in vitro and in vivo. Cancer Res 53: 2566-2570.
175. Yoshida S, Tanaka R, Ono M, Takai N, Saito T (1989). Analysis of mixed lymphocyte-tumor culture in patients with malignant brain tumor. J Neurosurg 71: 398-402.
176. Yuan F, Dellian M, Fukumura D, Leunig M, Berk DA, Torchilin VP, Jain RK (1995). Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 55: 3752-3756.
177. 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies. Cancer Res 49: 2807-2813.
178. Zimmerman L, Parr B, Lendahl U, Cunningham M, McKay R, Gavin B, Mann J, Vassileva G, McMahon A (1994). Independent regulatory elements in the nestin gene direct transgene expression to neural stem cells or muscle precursors. Neuron 12: 11-24.
179. Zünkeller B, Carson RE, Olson J, Blasberg RG, DeVroom H, Lutz RJ, Saris SC, Wright DC, Kammerer W, Patronas NJ, Dedrick RL, Herscovitch P, Oldfield EH (1996). Quantification and pharmacokinetics of blood-brain barrier disruption in humans. J Neurosurg 85: 1056-1065.